BioCryst Pharmaceuticals, Inc.

Good morning and welcome to the BioCHRIST Q1 2023 earnings conference call. All participants will be in listen-only mode. Should you need assistance, please signal conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then or your telephone keypad. To withdraw your question, please press star then too. Please note this event is being recorded. I'd now like to turn the call to John Bluth at Biochrist. Please go ahead.

Thank you very much. Good morning and welcome to Biochrist's first quarter 2023 corporate update and financial results conference call. Today's press release and accompanying slides are available on our website. Participating with me today are CEO John Stonehouse, CFO Anthony Doyle, Chief Commercial Officer Charlie Geyer, and Chief R&D Officer Dr. Helen Thackeray. Following our remarks, we'll answer your questions. Before we begin, please note that today's conference call will contain forward-looking statements, including those statements regarding future results on audited and forward-looking financial information, as well as the company's future performance and or achievements. These statements are subject to known and unknown risks and uncertainties, which may cause our actual results, performance, or achievements to be materially different from any future results or performance expressed or implied in this presentation. You should not place undue reliance on these forward-looking statements. For additional information, including a detailed discussion of our risk factors, please refer to the company's documents filed with the Securities and Exchange Commission, which are accessed on our website. I'd now like to turn the call over to John Stonehouse.

Thanks, John. The launch of Orladeo remains very strong now entering the third year. Charlie will share the details, and when you hear the total number of patients on therapy and the growth rates of adding new patients both year over year and quarter over quarter, you should understand why we remain very confident in our guidance of no less than $320 million this year and $1 billion at peak. The large base of patients on therapy and the consistent number of new patients starts each quarter reflect a steady upward trajectory. And this is just the beginning as there's so many more patients yet to try Orladeo. We have a once a day therapy in an injectable marketplace. It makes sense that more and more patients are wanting to try it, and many see great benefit and tell us it's changed their lives. Beyond this, we will continue to invest in Orlodeo R&D to reach more patients and create even greater value. We will do this by adding more countries around the world where patients gain access to Orlodeo and by expanding the label like we're doing with the pediatric program. We will also continue to invest wisely and find the next Orladeo through our pipeline and discovery efforts. Our goal is to find another rare disease target where we're able to bring a best-in-class medicine to patients while balancing the risk inherent in drug development. Lastly, we have improved our already strong financial position by the recent refinancing. This was hard to do in the current environment, but Anthony and team got us better terms on our debt and push the repayment out to a time where we should be much closer to peak sales. This dramatically reduces our dependence on the capital markets and allows us to focus on the execution of our plan by growing Orladeo and finding another molecule where we can repeat the Orladeo success. That will lead to adding real value today and even more value in the future for patients and shareholders. Now I'll turn the call over to Anthony.